Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.
about
Acute lymphoblastic leukaemiaBeyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute LeukemiaChildhood acute myeloid leukaemiaFISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisFeasibility of treating post-transplantation minimal residual disease in children with acute leukemia.Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantationProphylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.A multigene array for measurable residual disease detection in AML patients undergoing SCTImatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04New frontiers in pediatric Allo-SCT.Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation.Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Natural killer cell therapy in children with relapsed leukemia.Measurements of treatment response in childhood acute leukemia.Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid LeukemiaHematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry.Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia.Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective reviewNewly established stem cell transplant program: 100 days follow-up of patients and its comparison with published Indian literature.The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.Acute myeloid leukemia: 2013 update on risk-stratification and management.Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia?Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.A critical review of which children with acute myeloid leukaemia need stem cell procedures.How I treat paediatric relapsed acute myeloid leukaemia.New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.New approaches for the immunotherapy of acute myeloid leukemia.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia.Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.Predicting Chemotherapy Resistance in AML.
P2860
Q24602387-8CA6DA59-43B6-4C1A-96A4-9981158007D9Q26781328-AD969F24-17AA-4D31-B744-4EA8FBA991C1Q27005960-B4E97928-D77E-46CB-9AF7-CFF36C053522Q33641201-E87D909E-500A-4602-8103-D7D4C8008DF3Q33815986-8AA8F799-BB7A-4CDE-8A15-16831F794DF8Q33831349-FE68E236-1763-419C-A75F-7D1DA5600B94Q34627218-5D402B94-67AC-44F6-9168-1B761E7DBE58Q35100974-9CFEEB5D-8CE1-459A-8BDC-C36219FE1413Q35582360-18912309-4390-4490-9198-A0BA8BC98D0BQ35602127-D4F2527E-2522-4C5C-8F0E-1361343CAF9AQ35628739-971E2140-D2E9-4A5E-81A7-10389E64E290Q35752737-E73CA870-6804-4AF1-AC70-7E69881FBCC5Q35992927-47033FC2-DAD2-4762-B2A1-E1539AE0C10CQ36053792-61B311A4-6C0F-4617-A955-4C3CCE389917Q36251948-FFBCB03D-509E-44C7-951D-45B8D513EB6BQ36513773-5C9A4327-80A0-467F-9B25-CA739176B29FQ36723108-05E59044-8248-4416-A11A-1C2F7B8EBBC2Q37060668-E735D4D9-2B01-4035-BAF1-5D390EE63C34Q37148120-A3F73A96-67A8-4C3B-9297-3E9730257247Q37151698-21F68479-08B0-41A9-A48A-B446A78F15B6Q37233236-62F05630-FA2E-4DBC-90C6-161C601C165EQ37265107-889E2DD3-94D2-437E-AD45-029A66089207Q37670062-727768C6-180E-4B42-A015-5F580000B887Q38092771-559F50BF-988C-47F6-9EBC-D04F2DB7EF9FQ38096909-14AC9DF0-21F9-47BD-8C58-7A5F3E139EE6Q38105123-C1DC197C-7767-4915-8B91-ADCB5BD2F840Q38155455-B2771B61-B1F8-46E5-9541-737B3F19A1EDQ38196743-4E549472-6713-4BA2-A547-E8BF733472D6Q38205864-5972A950-87D3-4019-A13E-E5EBEECF0534Q38212509-F7124DA9-51FA-4722-9564-59BDB4FDE50BQ38220573-6D308967-5610-4546-824A-876DB8FEA850Q38482206-846C36B3-3C4D-47AB-8A20-0F720186F8F3Q38494659-02BCBD10-014E-44F0-A4C3-65F325E0E189Q38681322-DD915246-5552-473A-8033-4FF0AAACA473Q38698520-43C565FE-7150-466A-A093-FFE1D0C544AFQ38821563-59FDDFE3-769F-4A52-B76F-50972BE76675Q38863489-2D8B2096-BFB4-465F-A7AA-A66EE8A2064CQ38881996-86417A80-C7AC-444D-920F-426D26336783Q39031833-8AD2B73B-A931-4AEA-B6DA-975E0DAD3DA5Q39233284-2E84F3F1-B5D5-4715-9BF3-78EEBA998246
P2860
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Detectable minimal residual di ...... with very-high-risk leukemia.
@ast
Detectable minimal residual di ...... with very-high-risk leukemia.
@en
type
label
Detectable minimal residual di ...... with very-high-risk leukemia.
@ast
Detectable minimal residual di ...... with very-high-risk leukemia.
@en
prefLabel
Detectable minimal residual di ...... with very-high-risk leukemia.
@ast
Detectable minimal residual di ...... with very-high-risk leukemia.
@en
P2093
P2860
P50
P1433
P1476
Detectable minimal residual di ...... with very-high-risk leukemia.
@en
P2093
Asha Pillai
Christine Hartford
Dario Campana
David Shook
Deqing Pei
Elaine Coustan-Smith
Hiroto Inaba
John T Sandlund
Joseph H Laver
P2860
P304
P356
10.1182/BLOOD-2012-02-409813
P407
P577
2012-04-19T00:00:00Z